ProfileGDS5678 / 1438428_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 68% 72% 54% 57% 56% 56% 53% 52% 56% 56% 57% 56% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.422555
GSM967853U87-EV human glioblastoma xenograft - Control 24.1236268
GSM967854U87-EV human glioblastoma xenograft - Control 34.5667172
GSM967855U87-EV human glioblastoma xenograft - Control 43.2906754
GSM967856U87-EV human glioblastoma xenograft - Control 53.4101357
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.498856
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4943656
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2776653
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2496852
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4047656
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4235356
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4002857
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4286256
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4145756